Robert Lakin

Robert Lakin

InvestorPlace Contributor

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

Chinese EV Stocks: Why LI, XPEV and NIO Stocks Are Revving Up Today

By Robert Lakin, InvestorPlace Contributor

Shares of leading Chinese EV stocks were on the move ahead of trading as the manufacturers continue to report significant gains in deliveries in May. XPEV stock led the way, followed closely by NIO stock and Li Auto shares.

AMC Stock: The $230M News Lifting AMC Entertainment Today

By Robert Lakin, InvestorPlace Contributor

AMC Entertainment got $230 million from Mudrick Capital to use just as Americans look set to resume their movie-going ways. AMC stock has been a retail meme favorite for most of 2021.

XPEV Stock: What Has Shares of Chinese EV Producer Xpeng Surging Today?

By Robert Lakin, InvestorPlace Contributor

Xpeng reported near-record deliveries in May. While XPEV is down nearly 25% in 2021, the electric vehicle maker is making big strides in distinguishing its cars in a crowded Chinese market.

ZSAN Stock: Why Zosano Pharma Is Racing Higher Today

By Robert Lakin, InvestorPlace Contributor

ZSAN stock is zooming higher on Thursday after Zosano Pharma shared positive data on its proprietary migraine treatment.

OCGN Stock: The Big FDA News Lifting Ocugen Shares Today

By Robert Lakin, InvestorPlace Contributor

Ocugen has swung to new highs and lows this year on news around its partnership for Covaxin. Today's announcement could stoke further progress speculation.

Load More